ALK mutation

Initial treatment with chemoimmunotherapy was complicated by hypersensitivity reactions to nivolumab and paclitaxel, leading to a brief hospitalization...This case demonstrates the efficacy of neoadjuvant alectinib in managing ALK-mutant stage III lung adenocarcinoma, highlighting the potential benefits of targeted therapy in the neoadjuvant setting. Further studies are needed to establish optimal treatment protocols for patients with ALK-positive lung cancer.

Our results confirm that cell surface NCL is a biomarker and a potential target for NB, paving the way for further investigations aimed at the future clinical translation of innovative combination strategies against NB.

This study demonstrated encouraging intracranial efficacy and acceptable safety of bevacizumab plus chemotherapy in patients with non-squamous NSCLC and brain metastases in the first-line setting.

P1, N=115, Active, not recruiting, Daiichi Sankyo | Trial completion date: Oct 2025 --> Mar 2027

Here, we present a patient diagnosed with high grade metastatic inflammatory myofibroblastic tumor driven by a RANBP2::ALK fusion, who later developed an ALK G1202R resistance mutation in the setting of treatment with crizotinib. The patient remains without evidence of disease now 18 months after discontinuing adjuvant lorlatinib. This case illustrates the importance of serial molecular profiling to guide selection of the optimal ALK inhibitor for the best clinical outcomes.

Squamous cell carcinomas and poorly differentiated tumors accelerated nodule growth. Gene mutations drove the differentiation of NSCLC cells but did not regulate their growth rate.

P2, N=161, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Dec 2029 --> Dec 2026 | Trial primary completion date: Dec 2029 --> Dec 2026

P1/2, N=51, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=242 --> 51 | Trial primary completion date: Dec 2027 --> May 2025

Several ALK inhibitors, like crizotinib, ceritinib, lorlatinib, repotrectinib, and alectinib, have shown different levels of success, but resistance to these treatments is still a big challenge. While ALK inhibitors have shown promise, resistance mechanisms necessitate the development of combination therapies and next-generation inhibitors. Future research should focus on optimizing targeted treatment strategies to improve survival outcomes in pediatric patients with ALK-positive neuroblastoma.

Young patients diagnosed with lung cancer are less likely to be diagnosed in a curable stage. The pathology and smoking habits differ significantly from patients above fifty years. While pending screening is important for the older population of smokers, it remains essential to consistently address the need for early diagnosis in the young population to prevent exacerbating existing disparities.

P2, N=61, Not yet recruiting, Beijing Friendship Hospital ,Capital Medical University; Beijing Friendship Hospital ,Capital Medical University

P2, N=62, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University